Neuro-Bio is a privately owned biotech, spun out of Oxford University, with a therapeutic focus on neurodegenerative disease. The company has discovered a novel molecule (T14) which is toxic in the adult brain and shown to be a potential key driver of neurodegeneration.

This distinct mechanism is utilised by Neuro-Bio to develop exciting new drugs to treat Alzheimer’s disease (AD), alongside a biomarker which can diagnose AD prior to the onset of symptoms.


The disruptive approach of Neuro-Bio has:

  • Identified the subset of cells vulnerable to Alzheimer’s disease (AD)
  • Explained the reason they are prone to degenerate
  • Identified the key pivotal toxic peptide (‘T14’) driving this process
  • Proved that T14 is a feature of the AD brain
  • Developed a novel animal model based on T14
  • Devised a possible test whereby T14 could be a biomarker of AD
  • Identified the T14 target receptor
  • Designed a T14 blocker as an effective therapeutic drug for AD, with proven behavioural and histological effects


“Dr Greenfield and her colleagues at Neuro-Bio have developed a novel, innovative, and potentially very fruitful approach to the treatment of Alzheimer’s disease.

The work represents an excellent example of translational research in which a finding in basic neurobiology has been linked to key aspects of human disease.” Dr Richard Mohs, Chief Scientific Officer for the Global Alzheimer’s Platform (GAP) Foundation.

NeuroBio logo

Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates from Neuro-Bio

You have Successfully Subscribed!